Heron Therapeutics HRTX 深 沪
等待开盘 10-08 09:30:00 美东时间
0.3843
+0.053
+15.86%
华盛通- 最 高0.39
- 今 开0.3285
- 成交量 367.84万股
- 最 低 0.3255
- 昨 收 0.3317
- 总市值 7296.02万
- 52周最高 1.575
- 市盈率 静 --
- 换手率 1.94%
- 52周最低 0.261
- 委 比 -99.06%
- 总股本 1.90亿
- 历史最高 42.90
- 量 比 1.23
- 振 幅 19.45%
- 历史最低 0.16
- 每 手 1
- 风险率 0.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Heron Therapeutics Expands U.S. Portfolio Through Licensing Deal
Heron Therapeutics ( ($HRTX) ) has provided an update. On September 23, 2026, H...
09-30 05:30
Heron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License Agreement
On September 23, 2026 (the "Effective Date"), Heron Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a multi-product Development and License Agreement (the "License Agreement") with Long Grove Pharmaceuticals, LLC, a Delaware limited liability company ("Long Grove"), and Caps...
09-30 05:07
Heron Therapeutics Extends Tax Benefit Preservation Plan Timeline
The latest update is out from Heron Therapeutics ( ($HRTX) ). On August 13, 202...
08-15 05:18
HC Wainwright & Co. Downgrades Heron Therapeutics to Neutral
HC Wainwright & Co. analyst Brandon Folkes downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Neutral.
08-11 20:31
Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-11 02:00
美股大行评级 | 火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元
火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元；犹他美容(ULTA)惨遭12家大行下调目标价>>
06-04 11:36
Needham Downgrades Heron Therapeutics to Hold
Needham analyst Serge Belanger downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Hold.
06-03 18:16
Heron Therapeutics To Appeal Delaware Court Ruling Invalidating Two CINVANTI Patents In Litigation With Azurity
Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent
06-02 20:21
Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.
Heron Therapeutics shares are trading lower after the company reported worse-th...
05-11 20:56
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
